Abstract
Background: As a common systemically muscular-skeleton disorder of aging, osteoporosisis is characterized by the uninterrupted deconstruction in osseous microarchitecture. Osteoporosis can consequently lead to a significantly high risk of osteoporotic fractures, such as Osteoporotic Vertebral Compressive Fractures [OVCF] in the spine and osteoporotic femoral neck fractures in the hip joint, which can significantly increase the numbers of mortality and morbidity in elderly people, especially in postmenopausal women.
Methods: In addition, vitamin K has been demonstrated to play a key role in inhibiting osteoporotic fractures among postmenopausal women, but its long-term benefits, potential harms, and side effects of the combination between vitamin K and other anti-osteoporosis medicines, such as bisphosphonates or teriparatide still remain to be extensively studied. Therefore, the present study aimed to systematically reviewed previously published literature on the role of vitamin K in the treatment of osteoporosis. We currently, via multiple query strategies, searched the relevant literature in Cochrane and PubMed from January 2010 to December 2019.
Results: Subsequently, we conducted the systematic review according to the standard guideline of Preferred Reporting Item for Systematic Reviews and Meta-Analyses [PRISMA].
Conclusion: Finally, ten relevant studies met our current criteria for inclusion; subsequently, we followed the PRISMA guideline, then systematically reviewed each study by categorizing the data sources and analytical approaches in each study, while setting up variables and defining each study's outcomes.
Keywords: Osteoporosis, vitamin K, drug target, osteocalcin, randomized controlled trial (RCT), OVCF.
Graphical Abstract
[1]
Asadullah M, Ikram R, Qazi S. Vertebral spine osteoporosis treatment efficacy in local population: A clinical study. Pak J Pharm Sci 2018; 31(6): 2347-53.
[PMID: 30473503]
[PMID: 30473503]
[2]
Fischer CR, Vasudeva E, Beaubrun B, Messer Z, Cazzullino A, Lehman R. Osteoporosis knowledge among spine surgery patients. Int J Spine Surg 2018; 12(6): 689-94.
[http://dx.doi.org/10.14444/5086] [PMID: 30619672]
[http://dx.doi.org/10.14444/5086] [PMID: 30619672]
[3]
Rexiti P, Aierken G, Wang S, et al. Anatomical research on strength of screw track fixation in novel cortical bone trajectory for osteoporosis lumbar spine. Am J Transl Res 2019; 11(11): 6850-9.
[PMID: 31814892]
[PMID: 31814892]
[4]
Shayganfar A, Khodayi M, Ebrahimian S, Tabrizi Z. Quantitative diagnosis of osteoporosis using lumbar spine signal intensity in magnetic resonance imaging. Br J Radiol 2019; 92(1097): 20180774.
[http://dx.doi.org/10.1259/bjr.20180774] [PMID: 30759992]
[http://dx.doi.org/10.1259/bjr.20180774] [PMID: 30759992]
[5]
Buckley L, Guyatt G, Fink HA, et al. 2017 American college of Rheumatology guideline for the prevention and treatment of Glucocorticoid- Induced Osteoporosis. Arthritis Rheum 2017; 69(8): 1521-37.
[http://dx.doi.org/10.1002/art.40137] [PMID: 28585373]
[http://dx.doi.org/10.1002/art.40137] [PMID: 28585373]
[6]
Carter M. Prevention of glucocorticoid-induced osteoporosis: Clinical audit to evaluate the implementation of national osteoporosis guideline group 2017 guidelines in a primary care setting. J Clin Densitom 2019; 22(1): 25-30.
[http://dx.doi.org/10.1016/j.jocd.2018.03.009] [PMID: 29729949]
[http://dx.doi.org/10.1016/j.jocd.2018.03.009] [PMID: 29729949]
[7]
Hauk L. Treatment of low BMD and osteoporosis to prevent fractures: Updated guideline from the ACP. Am Fam Physician 2018; 97(5): 352-3.
[PMID: 29671503]
[PMID: 29671503]
[8]
Kanis JA, Cooper C, Rizzoli R, Reginster JY. Review of the guideline of the american college of physicians on the treatment of osteoporosis. Osteoporos Int 2018; 29(7): 1505-10.
[http://dx.doi.org/10.1007/s00198-018-4504-y] [PMID: 29869039]
[http://dx.doi.org/10.1007/s00198-018-4504-y] [PMID: 29869039]
[9]
Zhao Y, Huang M, Ding J, et al. Prediction of abnormal bone density and osteoporosis from lumbar spine MR using modified dixon quant in 257 subjects with quantitative computed tomography as reference. J Magn Reson Imaging 2019; 49(2): 390-9.
[http://dx.doi.org/10.1002/jmri.26233] [PMID: 30390360]
[http://dx.doi.org/10.1002/jmri.26233] [PMID: 30390360]
[10]
Ballini A, Scacco S, Coletti D, Pluchino S, Tatullo M. Mesenchymal stem cells as promoters, enhancers, and playmakers of the translational regenerative medicine. Stem Cells Int 2017; 2017: 3292810.
[http://dx.doi.org/10.1155/2017/3292810] [PMID: 28740512]
[http://dx.doi.org/10.1155/2017/3292810] [PMID: 28740512]
[11]
Ballini A, Cantore S, Scacco S, Coletti D, Tatullo M. Mesenchymal stem cells as promoters, enhancers, and playmakers of the translational regenerative medicine 2018. Stem Cells Int 2018; 2018: 6927401.
[http://dx.doi.org/10.1155/2018/6927401] [PMID: 30510586]
[http://dx.doi.org/10.1155/2018/6927401] [PMID: 30510586]
[12]
Paduano F, Marrelli M, Palmieri F, Tatullo M. Cd146 expression influences periapical cyst mesenchymal stem cell properties. Stem Cell Rev Rep 2016; 12(5): 592-603.
[13]
Ballini AA-O, Boccaccio A, Saini R, Van Pham PA-O, Tatullo MA-O. Dental-derived stem cells and their secretome and interactions with bioscaffolds/biomaterials in regenerative medicine: From the in vitro research to translational applications. Stem Cells Int 2017; 2017: 6975251.
[14]
Jaghsi S, Hammoud T, Haddad S. Relation between circulating vitamin K1 and osteoporosis in the lumbar spine in syrian post-menopausal women. Open Rheumatol J 2018; 12: 1-9.
[http://dx.doi.org/10.2174/1874312901812010001] [PMID: 29541269]
[http://dx.doi.org/10.2174/1874312901812010001] [PMID: 29541269]
[15]
Pearson DA. Bone health and osteoporosis: The role of vitamin K and potential antagonism by anticoagulants. Nutr Clin Pract 2007; 22(5): 517-44.
[http://dx.doi.org/10.1177/0115426507022005517] [PMID: 17906277]
[http://dx.doi.org/10.1177/0115426507022005517] [PMID: 17906277]
[16]
K Giri T, Newton D, Chaudhary O, et al. Maximal dose-response of Vitamin-k2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis. Int J Vitam Nutr Res 2020; 90(1-2): 42-8.
[http://dx.doi.org/10.1024/0300-9831/a000554] [PMID: 30816822]
[http://dx.doi.org/10.1024/0300-9831/a000554] [PMID: 30816822]
[17]
Calzetta L, Pistocchini E, Leo A, et al. Anthelminthic medicinal plants in veterinary Ethnopharmacology: A network meta-analysis following the PRISMA-P and PROSPERO recommendations. Heliyon 2020; 6(2): e03256.
[http://dx.doi.org/10.1016/j.heliyon.2020.e03256] [PMID: 32055724]
[http://dx.doi.org/10.1016/j.heliyon.2020.e03256] [PMID: 32055724]
[18]
Dai L, Ooi VV, Zhou W, Ji G. Acupoint embedding therapy improves nonalcoholic fatty liver disease with abnormal transaminase: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2020; 99(3): e18775.
[http://dx.doi.org/10.1097/MD.0000000000018775] [PMID: 32011470]
[http://dx.doi.org/10.1097/MD.0000000000018775] [PMID: 32011470]
[19]
Yuan T, Xiong J, Wang X, et al. The effectiveness and safety of Moxibustion for treating knee osteoarthritis: A PRISMA compliant systematic review and meta-analysis of randomized controlled trials. Pain Res Manag 2019; 2019: 2653792.
[http://dx.doi.org/10.1155/2019/2653792] [PMID: 31949547]
[http://dx.doi.org/10.1155/2019/2653792] [PMID: 31949547]
[20]
Zhang P, Liu B. Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and Neuromyelitis Optica Spectrum Disorder: A PRISMA-compliant meta-analysis. Bone Marrow Transplant 2020; 55(10): 1928-34.
[http://dx.doi.org/10.1038/s41409-020-0810-z] [PMID: 32020080]
[http://dx.doi.org/10.1038/s41409-020-0810-z] [PMID: 32020080]
[21]
Nagura N, Komatsu J, Iwase H, et al. Effects of the combination of vitamin K and teriparatide on the bone metabolism in ovariectomized rats. Biomed Rep 2015; 3(3): 295-300.
[http://dx.doi.org/10.3892/br.2015.431] [PMID: 26137225]
[http://dx.doi.org/10.3892/br.2015.431] [PMID: 26137225]
[22]
Huang Y. Combined treatment of vitamin K and teriparatide on bone metabolism and biomechanics in rats with Osteoporosis. Exp Ther Med 2018; 15(1): 315-9.
[PMID: 29387190]
[PMID: 29387190]
[23]
Hidaka T, Hasegawa T, Fujimura M, Sakai M, Saito S. Treatment for patients with postmenopausal osteoporosis who have been placed on HRT and show a decrease in bone mineral density: Effects of concomitant administration of Vitamin K(2). J Bone Miner Metab 2002; 20(4): 235-9.
[http://dx.doi.org/10.1007/s007740200034] [PMID: 12115070]
[http://dx.doi.org/10.1007/s007740200034] [PMID: 12115070]
[24]
Kasukawa Y, Miyakoshi N, Ebina T, et al. Effects of risedronate alone or combined with Vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. J Bone Miner Metab 2014; 32(3): 290-7.
[http://dx.doi.org/10.1007/s00774-013-0490-5] [PMID: 23846118]
[http://dx.doi.org/10.1007/s00774-013-0490-5] [PMID: 23846118]
[25]
Iwamoto J. Vitamin K2 therapy for postmenopausal osteoporosis. Nutrients 2014; 6(5): 1971-80.
[http://dx.doi.org/10.3390/nu6051971] [PMID: 24841104]
[http://dx.doi.org/10.3390/nu6051971] [PMID: 24841104]
[26]
Cheung AM, Tile L, Lee Y, Tomlinson G, Hawker G, Scher J. Vitamin k supplementation in postmenopausal women with osteopenia [ecko trial]: A randomized controlled trial. PLoS Med 2008; 5(10): e196.
[27]
Knapen MHJ, Drummen NE, Smit E, Vermeer C, Theuwissen E. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int 2013; 24(9): 2499-507.
[http://dx.doi.org/10.1007/s00198-013-2325-6] [PMID: 23525894]
[http://dx.doi.org/10.1007/s00198-013-2325-6] [PMID: 23525894]
[28]
Rønn SH, Harsløf T, Pedersen SB, Langdahl BL. Vitamin K2 (Menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in Postmenopausal women. Eur J Endocrinol 2016; 175(6): 541-9.
[http://dx.doi.org/10.1530/EJE-16-0498] [PMID: 27625301]
[http://dx.doi.org/10.1530/EJE-16-0498] [PMID: 27625301]
[29]
Purwosunu Y, Muharram , Rachman IA, Reksoprodjo S, Sekizawa A. Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia. J Obstet Gynaecol Res 2006; 32(2): 230-4.
[http://dx.doi.org/10.1111/j.1447-0756.2006.00386.x] [PMID: 16594930]
[http://dx.doi.org/10.1111/j.1447-0756.2006.00386.x] [PMID: 16594930]
[30]
Ishida Y, Kawai S. Comparative efficacy of hormone replacement therapy, Etidronate, Calcitonin, Alfacalcidol, and Vitamin K in postmenopausal women with osteoporosis: The yamaguchi osteoporosis prevention study. Am J Med 2004; 117(8): 549-55.
[http://dx.doi.org/10.1016/j.amjmed.2004.05.019] [PMID: 15465502]
[http://dx.doi.org/10.1016/j.amjmed.2004.05.019] [PMID: 15465502]
[31]
Knapen MHJ, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int 2007; 18(7): 963-72.
[http://dx.doi.org/10.1007/s00198-007-0337-9] [PMID: 17287908]
[http://dx.doi.org/10.1007/s00198-007-0337-9] [PMID: 17287908]
[32]
Kishimoto H, Fukunaga M, Kushida K, et al. Efficacy and tolerability of once-weekly administration of 17.5 mg Risedronate in Japanese patients with involutional Osteoporosis: A comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 2006; 24(5): 405-13.
[http://dx.doi.org/10.1007/s00774-006-0706-z] [PMID: 16937274]
[http://dx.doi.org/10.1007/s00774-006-0706-z] [PMID: 16937274]
[33]
Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23(4): 517-23.
[http://dx.doi.org/10.1210/er.2001-3002] [PMID: 12202466]
[http://dx.doi.org/10.1210/er.2001-3002] [PMID: 12202466]
[34]
Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of Osteoporosis treatment on mortality: A meta-analysis. J Clin Endocrinol Metab 2010; 95(3): 1174-81.
[http://dx.doi.org/10.1210/jc.2009-0852] [PMID: 20080842]
[http://dx.doi.org/10.1210/jc.2009-0852] [PMID: 20080842]
[35]
Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 2011; 96(4): 1006-14.
[http://dx.doi.org/10.1210/jc.2010-2730] [PMID: 21289270]
[http://dx.doi.org/10.1210/jc.2010-2730] [PMID: 21289270]
[36]
Shiraki M, Yamazaki Y, Shiraki Y, Hosoi T, Tsugawa N, Okano T. High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment. J Bone Miner Metab 2010; 28(5): 578-84.
[http://dx.doi.org/10.1007/s00774-010-0167-2] [PMID: 20221651]
[http://dx.doi.org/10.1007/s00774-010-0167-2] [PMID: 20221651]
[37]
Yonemura K, Kimura M, Miyaji T, Hishida A. Short-term effect of Vitamin K administration on Prednisolone- Induced loss of bone mineral density in patients with chronic clomerulonephritis. Calcif Tissue Int 2000; 66(2): 123-8.
[http://dx.doi.org/10.1007/PL00005832] [PMID: 10652960]
[http://dx.doi.org/10.1007/PL00005832] [PMID: 10652960]
[38]
Sasaki N, Kusano E, Takahashi H, et al. Vitamin K2 inhibits Glucocorticoid- Induced bone loss partly by preventing the reduction of Osteoprotegerin (OPG). J Bone Miner Metab 2005; 23(1): 41-7.
[http://dx.doi.org/10.1007/s00774-004-0539-6] [PMID: 15616893]
[http://dx.doi.org/10.1007/s00774-004-0539-6] [PMID: 15616893]
[39]
Shikano K, Kaneko K, Kawazoe M, Kaburaki M, Hasunuma T, Kawai S. Efficacy of Vitamin K2 for Glucocorticoid- Induced osteoporosis in patients with systemic autoimmune diseases. Intern Med 2016; 55(15): 1997-2003.
[http://dx.doi.org/10.2169/internalmedicine.55.6230] [PMID: 27477405]
[http://dx.doi.org/10.2169/internalmedicine.55.6230] [PMID: 27477405]
[40]
Matsunaga S, Ito H, Sakou T. The effect of vitamin K and D supplementation on ovariectomy- induced bone loss. Calcif Tissue Int 1999; 65(4): 285-9.
[http://dx.doi.org/10.1007/s002239900700] [PMID: 10485979]
[http://dx.doi.org/10.1007/s002239900700] [PMID: 10485979]
[41]
Douglas AS, Robins SP, Hutchison JD, Porter RW, Stewart A, Reid DM. Carboxylation of osteocalcin in postmenopausal osteoporotic women following vitamin K and D supplementation. Bone 1995; 17(1): 15-20.
[http://dx.doi.org/10.1016/8756-3282(95)00133-X] [PMID: 7577153]
[http://dx.doi.org/10.1016/8756-3282(95)00133-X] [PMID: 7577153]
[42]
Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (Menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in Osteoporosis. J Bone Miner Res 2000; 15(3): 515-21.
[http://dx.doi.org/10.1359/jbmr.2000.15.3.515] [PMID: 10750566]
[http://dx.doi.org/10.1359/jbmr.2000.15.3.515] [PMID: 10750566]
[43]
Inoue T, Fujita T, Kishimoto H, et al. Randomized controlled study on the prevention of Osteoporotic fractures (OF study): A phase IV clinical study of 15-mg Menatetrenone capsules. J Bone Miner Metab 2009; 27(1): 66-75.
[http://dx.doi.org/10.1007/s00774-008-0008-8] [PMID: 19082528]
[http://dx.doi.org/10.1007/s00774-008-0008-8] [PMID: 19082528]
Article Metrics
31
1